content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <!-- Generated by Workiva -->
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <cik>0001721108</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001492422</issuerCik>
        <issuerName>Apellis Pharmaceuticals, Inc.</issuerName>
        <secFileNumber>001-38276</secFileNumber>
        <issuerAddress>
          <com:street1>100 Fifth Avenue</com:street1>
          <com:city>Waltham</com:city>
          <com:stateOrCountry>MA</com:stateOrCountry>
          <com:zipCode>02451</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>617-977-5700</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>A. Sinclair Dunlop</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>Director</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>JP Morgan Securities LLC</name>
          <address>
            <com:street1>390 Madison Avenue</com:street1>
            <com:street2>6th Floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10017</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>24000</noOfUnitsSold>
        <aggregateMarketValue>1162800</aggregateMarketValue>
        <noOfUnitsOutstanding>118499945</noOfUnitsOutstanding>
        <approxSaleDate>11/09/2023</approxSaleDate>
        <securitiesExchangeName>NASDAQ</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Common Stock</securitiesClassTitle>
        <acquiredDate>12/21/2012</acquiredDate>
        <natureOfAcquisitionTransaction>Private Transaction</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>24000</amountOfSecuritiesAcquired>
        <paymentDate>12/21/2012</paymentDate>
        <natureOfPayment>N/A</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <remarks>The shares filed today will be sold by Epidarex Capital I, LP,   A. Sinclair Dunlop as Managing Partner</remarks>
      <noticeSignature>
        <noticeDate>11/09/2023</noticeDate>
        <signature>/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for A. Sinclair Dunlop</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 2994}]
text: 144
  0001721108
  XXXXXXXX
  LIVE
  0001492422
  Apellis Pharmaceuticals, Inc.
  001-38276
  100 Fifth Avenue
  Waltham
  MA
  02451
  617-977-5700
  A. Sinclair Dunlop
  Director
  Common Stock
  JP Morgan Securities LLC
  390 Madison Avenue
  6th Floor
  New York
  NY
  10017
  24000
  1162800
  118499945
  11/09/2023
  NASDAQ
  Common Stock
  12/21/2012
  Private Transaction
  Issuer
  N
  24000
  12/21/2012
  N/A
  Y
  The shares filed today will be sold by Epidarex Capital I, LP,   A. Sinclair Dunlop as Managing Partner
  11/09/2023
  /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for A. Sinclair Dunlop